Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8538-8543

  Chan, John K ^c   Loizzi, Vera ^a   Magistris, Alessandra ^a   Lin, Fritz ^a   Rutgers, Joanne ^b   Osann, Kathryn ^a   DiSaia, Philip J ^a   Berman, Michael L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOLECULAR MARKER; PROTEIN P53;

ADULT; ADVANCED CANCER; AGE; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MICROVASCULATURE; ONCOGENE NEU; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CASE-CONTROL STUDIES; FEMALE; HUMANS; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144224484     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0626     Document Type: Article

References (30)

1. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol 1985;92:839-42.
2. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer (Phila) 1993;71:606-14.
3. Chan JK, Loizzi V, Lin YG, et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003;102:156-61.
4. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999;5:587-91.
5. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
6. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
7. Schoell WM, Pieber D, Reich O, et al. Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer (Phila) 1997;80:2257-62.
8. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
9. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996;69:205-11.
10. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (Phila) 1997;80:98-106.
11. Ogawa S, Kaku T, Kobayashi H, et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 2002;176:111-8.
12. Giatromanolaki A, Koukourakis MI, Georgoulias V, et al. Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. Int J Cancer 1999;80:810-7.
13. Nakanishi Y, Kodama J, Yoshinouchi M, et al. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997;16:256-62.
14. Obermair A, Wasicky R, Kaider A, et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 1999;138:175-82.
15. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
16. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond) 1989;342:705-8.
17. Lavigueur A, Maltby V, Mock D, et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989;9:3982-91.
18. Jacobs IJ, Kohler MF, Wiseman RW, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (Bethesda) 1992;84:1793-8.
19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash DC) 1989;244:707-12.
20. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
21. Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science (Wash DC) 1988;240:1795-8.
22. Gadducci A, Viacava P, Cosio S, et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 2003;23:549-56.
23. Löscha A, Schindl M, Kohlberger P, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004;92:545-52.
24. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003;8:396-403.
25. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:881-90.
26. Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80.
27. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (Phila) 2003;97:1573-81.
28. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21:473-82.
29. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
30. Hurwitz H, Cartwright T, Hainsworth J, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. www.ASCO.org, May 2003. http://www.asco.org/hurwitz_no3646.